Get the Stockscreener App
62.00
7.45%
4.30
After Hours:
60.74
-1.26
-2.03%
Mbx Biosciences Inc stock is traded at $62.00, with a volume of 756.53K.
It is up +7.45% in the last 24 hours and up +104.76% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$57.70
Open:
$58.11
24h Volume:
756.53K
Relative Volume:
1.02
Market Cap:
$2.95B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-25.63
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
+12.32%
1M Performance:
+104.76%
6M Performance:
+90.48%
1Y Performance:
+381.37%
1-Day Range:
$56.17
$62.25
1-Week Range:
$55.05
$62.25
52-Week Range:
$9.63
$62.25
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
62.00 | 2.75B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences stock hits all-time high at 59.55 USD By Investing.com - Investing.com South Africa
MBX Biosciences on Track for Record High Close -- Data Talk - Moomoo
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy) - Seeking Alpha
Price to earnings forward of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
MBXMBX Biosciences Inc Options - Finviz
Paradigm Biocapital Advisors LP Acquires Significant Stake in MB - GuruFocus
MBX Biosciences Soars on Breakthrough Trial Momentum - TipRanks
Mbx biosciences stock hits all-time high of 54.98 USD - Investing.com
Mbx biosciences stock hits all-time high of 54.98 USD By Investing.com - Investing.com India
MBX Biosciences, Inc.(NasdaqGS:MBX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 2000 Value Benchmark - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS:MBX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to Russell 2000 Growth Benchmark - marketscreener.com
Does MBX (MBX) Joining Russell Growth Indexes Mark a Lasting Shift in Its Market Narrative? - simplywall.st
MBX Biosciences, Inc.(NasdaqGS: MBX) added to Russell 3000E Growth Benchmark - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) added to Russell 2500 Growth Benchmark - marketscreener.com
MBX Biosciences, Inc.(NasdaqGS: MBX) dropped from Russell 3000 Value Benchmark - marketscreener.com
MBX Biosciences, Inc. Actuals & Estimates (NASDAQ:MBX) - TradingView
MBX Biosciences Rises After Positive Clinical Trial Update - TipRanks
MBX Forecast — Price Target — Prediction for 2027 - TradingView
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Paradigm entities disclose multi-million share stakes in MBX (MBX) - Stock Titan
MBX Biosciences highlights sustained calcium control in rare disease - MSN
MBX Biosciences Soars on Breakthrough Trial Results - TipRanks
Mbx Biosciences stock hits all-time high at 45.88 USD By Investing.com - Investing.com Australia
Mbx Biosciences stock hits all-time high at 45.88 USD - Investing.com
MBX Biosciences shares fall despite positive one-year trial results for Canvuparatide (MBX) - MSN
MBX Biosciences Inc (MBX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MBX Biosciences Inc (MBX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MBX Biosciences Inc (MBX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity - TipRanks
MBX Biosciences Inc (MBX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MBX Biosciences Inc (MBX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MBX Biosciences Inc (MBX) Institutional Confidence - TradingKey
MBX Biosciences Inc (MBX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBX Biosciences Inc (MBX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MBX News | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
MBX updates data from mid-stage trial for endocrine disease therapy - MSN
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Yahoo! Finance Canada
Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk - Moomoo
MBX Biosciences (MBX) Slips 4.67% as Stock Tests Key Support LevelsHagopian Line - dars.gov.et
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Health Care Roundup: Market Talk - Moomoo
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) Share Price, MBX Stock News, MBX Share Price & Updates - Kalkine
Mbx Biosciences90% of Patients in Ole Rema - Moomoo
Street canvu MBX phase II HP data more than one way - BioWorld News
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):